therapeutic antibodies (e.g., OKT3)
GPTKB entity
Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:monoclonal_antibody |
| gptkbp:developedBy |
gptkb:biotechnology
|
| gptkbp:example |
gptkb:rituximab
gptkb:trastuzumab gptkb:OKT3 gptkb:adalimumab |
| gptkbp:mechanismOfAction |
binds to specific antigens
|
| gptkbp:regulates |
FDA approved
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
immunosuppression
cytokine release syndrome |
| gptkbp:target |
immune system
|
| gptkbp:usedFor |
immunosuppression
treatment of diseases |
| gptkbp:bfsParent |
gptkb:CD3ε
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
therapeutic antibodies (e.g., OKT3)
|